GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
The agreement reinforces GSK's oncology pipeline and gives Syndivia the scale to progress its promising asset. GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialise an antibody-drug conjugate (ADC) from Syndivia targeting metastatic castration-resistant prostate cancer.
According to reports, the agreement is worth up to £268 million, reflecting GSK's push to broaden its oncology pipeline. Syndivia, a France-based biotech firm specialising in next-generation ADCs, has shown this candidate delivered enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
GSK noted the therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.
No direct quote available in the text.
Author's summary: GSK acquires rights to Syndivia's ADC asset.
More News
- Paul Gauguin’s final self portrait—previously decried as fake—is authentic, museum concludes
- Almonty Industries to acquire tungsten project in Montana, US
- Why Impact Investing Might Collapse and How to Stop It (SSIR)
- LOOK Keo Vision Pedals Light the Way — Keo Blade Ceramic Vision, Keo 2 Max Vision & Vision Upgrade Kit
- In Review: Big-Ass Sword by Andreas Butzbach
- Cameco, Brookfield involved in $80 billion U.S. nuclear reactor deal
- Melissa second landfall in eastern Cuba Wednesday morning - The Weather Network
- Novartis Q3: new drugs step up as generics squeeze Entresto - Pharmaceutical Technology
- MLB: The Last 10 World Series MVPs
- VSee Awarded US Department of Health & Human Services FedRAMP High ATO